[Federal Register Volume 59, Number 44 (Monday, March 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5086]
[[Page Unknown]]
[Federal Register: March 7, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of Exclusive Patent License
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license in a limited field of use to practice the
inventions embodied in U.S. Patent Application 07/965,916, entitled
``Immunization Against Neisseria Gonorrhoea'' to Virus Research
Institute, Inc. having a place of business at Cambridge, Massachusetts.
The patent application has been continued, with additional data and
claims, in U.S. Patent Application 08/145,682, entitled ``Immunization
Against Neisseria Gonorrhoea and Neisseria Meningitides.'' The patent
rights in these inventions have been assigned to the United States of
America.
The prospective exclusive license will be for the field of vaccines
against Neisseria Gonorrhoea. It will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within sixty
days from the date of this published Notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
These inventions relate to novel immunization methods and
compositions useful in protecting against Neisseria Gonorrhoea and
Neisseria Meningitides infections. In particular, the invention claims
parenteral component priming-oral immunization methods and compositions
of matter useful in practicing these methods.
The availability of U.S. Patent Application 07/965,916 for
licensing was published in the April 15, 1993 edition of the Federal
Register. The availability of U.S. Patent Application 08/145,682 for
licensing has not previously been published.
ADDRESSES: Requests for a copy of the above identified patent
application, inquiries, comments and other materials relating to the
contemplated license should be directed to: Mr. Mark Hankins, J.D.,
Office of Technology Transfer, National Institutes of Health, Box OTT,
Bethesda, Maryland 20892 (telephone: (301) 496-7735; FAX: (301) 402-
0220). A signed confidentiality agreement will be required to receive
copies of the patent application. Properly filed competing applications
for a license filed in response to this notice will be treated as
objections to the grant of the contemplated license. Only written
comments and/or applications for a license which are received by the
NIH Office of Technology Transfer within sixty (60) days of this notice
will be considered.
Dated: February 18, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-5086 Filed 3-4-94; 8:45 am]
BILLING CODE 4140-01-M
